Developer docs
API playgroundTry for free, no card

Search company profiles

SauveBio

Full company profile

uuid00equwv

Namestring
SauveBio
Websiteurl
sauvebio.com
Company typeenum
Private
Founded yearint
2024
Descriptiontext

SauveBio is a privately held, for-profit contract research organization founded in 2024 and headquartered in Worcester, Massachusetts. The company specializes in flow cytometry, cell sorting, and biomedical laboratory support services, targeting research-oriented clients — likely academic labs, biotech startups, and pharmaceutical R&D groups — that require specialized cell-analysis capabilities outside their own infrastructure. The operating model is service-based: revenue is generated through project contracts, assay work, or hourly lab-services billing typical of small CROs, though no pricing, customer, or contract data are publicly disclosed.

The technical scope is centered on flow cytometry instrumentation and cell-sorting workflows rather than software, devices, or proprietary reagents. No information is available regarding equipment models, throughput capacity, assay menu, proprietary methods, or certifications (e.g., CLIA, GLP, ISO), which limits assessment of technical differentiation. The firm's web presence is currently a placeholder/verification page, indicating that public-facing marketing, scientific content, and client onboarding materials have not yet been published.

SauveBio is in an early-stage operating posture: 1-10 employees, no disclosed funding rounds, no announced partnerships, and no customer references. The leadership team comprises co-founders Hannah Sheehan (CEO, Co-Founder & CSO) and Jeffrey Sauve (President, Co-Founder & CFO), with Paul Wengender serving as Chief Commercial Officer, covering scientific, financial, and commercial functions. Given the recency of founding and the absence of disclosed financial, commercial, or technical details, the company should be evaluated as a nascent CRO whose commercial trajectory is yet to be evidenced.

Short descriptiontext

SauveBio is a Worcester, Massachusetts-based contract research organization founded in 2024 that provides flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The company operates as a small (1-10 employee) private CRO with a co-founder-led leadership team.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWorcester, United States
HQ citystring
Worcester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
contract research services, flow cytometry services, cell sorting services, biomedical lab support, preclinical research services
Industry3 codes
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Contract Research Services
Social media profiles1 record
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

SauveBio is a contract research organization (CRO) that provides specialized flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The firm supports academic, biotech, and pharmaceutical researchers who need expert cell analysis and separation capabilities delivered on a fee-for-service basis.

Differentiator
Functional benefit
Problem solved
Product and service3 records
1Flow cytometry services
CategoryContract research services
2Cell sorting services
CategoryContract research services
3Biomedical laboratory support services
CategoryContract research services
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provider of flow cytometry antibodies, reagents, and supporting services for cell biology and translational research, with growing presence in cell therapy and immuno-oncology. Comparable as a specialized provider of cytometry-related products and services.

TypeBroad incumbent
Description

Global CRO/CDMO offering discovery, preclinical, and central lab services with significant cell-based assay and cytometry capability. A scaled international competitor for outsourced lab services work.

TypeDirect peer
Description

Major instrument and reagent vendor for flow cytometry and cell sorting, with associated service and analysis offerings (e.g., Cytobank). Competes both as a tools vendor and as a service provider for cytometry-based clinical and research work.

TypeBroad incumbent
Description

Major CRO with discovery, safety assessment, and central lab services, including flow cytometry-enabled preclinical and translational work. Competes for cell therapy and immuno-oncology lab services contracts.

5Omiq
TypeEmerging player
Description

Cloud-based cytometry analysis platform serving translational and clinical researchers, including cell therapy workflows. Comparable as a specialized enabler of flow cytometry work and a potential partner or competitor depending on SauveBio's service mix.

TypeBroad incumbent
Description

Spin-out of Labcorp's clinical development business providing central lab and clinical trial services globally, including flow cytometry and biomarker testing. A scaled incumbent competing for the same CRO lab services budget.

TypeDirect peer
Description

Joint venture between IQVIA and Quest Diagnostics operating central and specialty clinical trial laboratories, including flow cytometry services for pharma and biotech sponsors. Q² Solutions is the closest scaled comparable to SauveBio's positioning as a clinical trial lab services CRO.

TypeBroad incumbent
Description

Global lab services group with significant central lab and specialty testing operations serving pharma sponsors, including flow cytometry and cell-based assay work. Operates broadly across life sciences testing and competes for the same outsourced lab services that SauveBio targets.

TypeBroad incumbent
Description

Dominant flow cytometry instrument and reagent vendor (including FlowJo analysis software) and operator of a clinical trial flow cytometry services business via BD's biosciences division. Competes for both instrument and outsourced cytometry service spend.

TypeEmerging player
Description

Specialty analysis platform for flow cytometry data with associated services used by clinical and translational researchers. Adjacent to SauveBio's offering as the data analysis layer over cytometry work.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SauveBio

Contract Research Servicessauvebio.com

SauveBio is a Worcester, Massachusetts-based contract research organization founded in 2024 that provides flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The company operates as a small (1-10 employee) private CRO with a co-founder-led leadership team.

What SauveBio does

SauveBio is a privately held, for-profit contract research organization founded in 2024 and headquartered in Worcester, Massachusetts. The company specializes in flow cytometry, cell sorting, and biomedical laboratory support services, targeting research-oriented clients — likely academic labs, biotech startups, and pharmaceutical R&D groups — that require specialized cell-analysis capabilities outside their own infrastructure. The operating model is service-based: revenue is generated through project contracts, assay work, or hourly lab-services billing typical of small CROs, though no pricing, customer, or contract data are publicly disclosed.

The technical scope is centered on flow cytometry instrumentation and cell-sorting workflows rather than software, devices, or proprietary reagents. No information is available regarding equipment models, throughput capacity, assay menu, proprietary methods, or certifications (e.g., CLIA, GLP, ISO), which limits assessment of technical differentiation. The firm's web presence is currently a placeholder/verification page, indicating that public-facing marketing, scientific content, and client onboarding materials have not yet been published.

SauveBio is in an early-stage operating posture: 1-10 employees, no disclosed funding rounds, no announced partnerships, and no customer references. The leadership team comprises co-founders Hannah Sheehan (CEO, Co-Founder & CSO) and Jeffrey Sauve (President, Co-Founder & CFO), with Paul Wengender serving as Chief Commercial Officer, covering scientific, financial, and commercial functions. Given the recency of founding and the absence of disclosed financial, commercial, or technical details, the company should be evaluated as a nascent CRO whose commercial trajectory is yet to be evidenced.

SauveBio firmographics

Firmographics
Name
SauveBio
Website
https://sauvebio.com
Company type
Private
Founded year
2024
Headcount range
1–10 employees
Short description
SauveBio is a Worcester, Massachusetts-based contract research organization founded in 2024 that provides flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The company operates as a small (1-10 employee) private CRO with a co-founder-led leadership team.
Ownership category
akta.pro rank

SauveBio industry classification

Industry
Product category
Contract Research Services
NAICS
Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Contract research services
  • Flow cytometry services
  • Cell sorting services
  • Biomedical lab support
  • Preclinical research services

Where SauveBio is headquartered

Location

Headquarters

HQ city
Worcester
HQ country
United States
HQ region
North America

Markets served

SauveBio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

SauveBio product offering

Product offering

Core offering

SauveBio is a contract research organization (CRO) that provides specialized flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The firm supports academic, biotech, and pharmaceutical researchers who need expert cell analysis and separation capabilities delivered on a fee-for-service basis.

Differentiator

Problem solved

Functional benefit

Products and services

  • Flow cytometry services
  • Cell sorting services
  • Biomedical laboratory support services

Companies that use SauveBio

Customer profile

Ideal customer profiles1 record

SauveBio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

SauveBio partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights2 records

SauveBio competitors and assessment

Company assessment

Direct peers

  • Cell Signaling Technology: Provider of flow cytometry antibodies, reagents, and supporting services for cell biology and translational research, with growing presence in cell therapy and immuno-oncology. Comparable as a specialized provider of cytometry-related products and services.
  • Beckman Coulter Life Sciences: Major instrument and reagent vendor for flow cytometry and cell sorting, with associated service and analysis offerings (e.g., Cytobank). Competes both as a tools vendor and as a service provider for cytometry-based clinical and research work.
  • Q² Solutions: Joint venture between IQVIA and Quest Diagnostics operating central and specialty clinical trial laboratories, including flow cytometry services for pharma and biotech sponsors. Q² Solutions is the closest scaled comparable to SauveBio's positioning as a clinical trial lab services CRO.

Broad incumbents

  • WuXi AppTec: Global CRO/CDMO offering discovery, preclinical, and central lab services with significant cell-based assay and cytometry capability. A scaled international competitor for outsourced lab services work.
  • Charles River Laboratories: Major CRO with discovery, safety assessment, and central lab services, including flow cytometry-enabled preclinical and translational work. Competes for cell therapy and immuno-oncology lab services contracts.
  • Labcorp Drug Development (Fortrea): Spin-out of Labcorp's clinical development business providing central lab and clinical trial services globally, including flow cytometry and biomarker testing. A scaled incumbent competing for the same CRO lab services budget.
  • Eurofins Scientific: Global lab services group with significant central lab and specialty testing operations serving pharma sponsors, including flow cytometry and cell-based assay work. Operates broadly across life sciences testing and competes for the same outsourced lab services that SauveBio targets.
  • BD Biosciences: Dominant flow cytometry instrument and reagent vendor (including FlowJo analysis software) and operator of a clinical trial flow cytometry services business via BD's biosciences division. Competes for both instrument and outsourced cytometry service spend.

Emerging players

  • Omiq: Cloud-based cytometry analysis platform serving translational and clinical researchers, including cell therapy workflows. Comparable as a specialized enabler of flow cytometry work and a potential partner or competitor depending on SauveBio's service mix.
  • FlowJo / Becton Dickinson: Specialty analysis platform for flow cytometry data with associated services used by clinical and translational researchers. Adjacent to SauveBio's offering as the data analysis layer over cytometry work.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

SauveBio social profiles

Digital presence

SauveBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SauveBio leadership team

Management profile

Number of profiles

Profiles3 records

SauveBio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SauveBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SauveBio

What does SauveBio do?

SauveBio is a contract research organization (CRO) that provides specialized flow cytometry, cell sorting, and biomedical laboratory support services to research clients. The firm supports academic, biotech, and pharmaceutical researchers who need expert cell analysis and separation capabilities delivered on a fee-for-service basis.

When was SauveBio founded?

SauveBio was founded in 2024. It employs 1 to 10 people.

Where is SauveBio based?

SauveBio is headquartered in Worcester, United States, in the North America region.

Who are SauveBio's main competitors?

Direct peers on record are Cell Signaling Technology, Beckman Coulter Life Sciences and Q² Solutions. Broad incumbents are WuXi AppTec, Charles River Laboratories, Labcorp Drug Development (Fortrea), Eurofins Scientific and BD Biosciences. Emerging players are Omiq and FlowJo / Becton Dickinson.

Does SauveBio have an API?

No public API is recorded for SauveBio.

What industry is SauveBio in?

SauveBio's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs, with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 54171 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals